|
|
|
| home > ebr > current issue |
|
|
 PUBLICATIONS |
European Biopharmaceutical Review |
|
|
|
|
|
 |
| |
|
|
|
|
|
Biomarkers for Rare Diseases
Jewel Biomarkers Can Be Found By Digging in the Right Mine
The future of biomarkers is bursting with potential, and surrogate biomarkers are now making way for the development of diagnostic, therapeutic, and prognostic biomarkers, enthuses Professor Hermann Mascher at pharm-analyt Labor.
|
|
|
|
Biomarkers: The Promise of Personalised Medicine
The Road to Success
Dr Karen Hills and Professor Ken Smith at PredictImmune revisit the history of biomarkers and draw comparisons to more modern examples, demonstrating how biomarkers have become drivers for a more personalised approach to medicine.
|
|
|
|
Predicting the Health of Future Generations with High-Resolution NMR
Trusting in Biobanking
Professor Matthias Nauck at University Medicine Greifswald introduces nuclear magnetic resonance spectroscopy as a means to enhance biobanking, ultimately progressing modern research techniques such as genomics and personalised medicine.
|
|
|
|
|
Laying the Foundation for Successful Advanced Therapies
Bridging the Gap
It is more important than ever for apheresis centres to keep up with the quickly evolving cell therapy landscape, and particular attention needs to be paid to starting materials, urge Dominic Clarke PhD and Brad N Taylor PhD at HemaCare.
|
|
|
|
Cell and Gene Therapy Development
Opportunities and Challenges in Cancer Innovations
Following some suggestions that almost all cancer treatments will eventually be based on cell and gene therapy approaches, Dr Ger Brophy at Avantor takes a step back to evaluate their progress and what is needed to reap their full potential.
|
|
|
|
|
Making Metabolites
Accessing Difficult-to-Synthesise Metabolites in Drug Development Programmes
Julia Shanu-Wilson at Hypha Discovery reviews case studies where different metabolite types, accessed through biological means, have been utilised and summarises the challenges and solutions met in their provision.
|
|
|
|
Rewriting Drug Discovery and Development
The Authenticity of Synthetics
The impact of synthetic biology is forecast to be broad, as explained by Evonetix’s Dr Tim Brears who sheds light on its potential to empower drug discovery, with particular regard towards DNA sequencing.
|
|
|
|
|
Q&A: The Growth of Advanced Therapy Medicinal Products
A New Class of Innovation
eXmoor Pharma Concepts’ Dr Angela Obsorne talks to EBR about the promise of advanced therapy medicinal products and the impact of Brexit on the UK's approach to these.
|
|
|
|
|
Ligand-Receptor Identification Methodologies
Details Matter
Protein-protein interaction technologies can only go so far in detecting extracellular interactions, begging the need for alternative methodologies, express Dr Maria P Pavlou and Dr Paul Helbling at Dualsystems Biotech.
|
|
|
|
Improving Study Outcomes
eCOA Technology in Vaccine Clinical Trials
Vaccine development can be hindered by the processing of large volumes of manual data. Katie Garner at CRF Bracket demonstrates how integrating electronic clinical outcome assessment can combat the burden.
|
|
|
|
Measuring the Overall Cost of Clinical Drug Trials in Canada
Pricing Clinical Research in the Canadian Industry
Canadian R&D is gaining momentum as the federal and provincial governments gauge the necessary tools to progress innovation. Dr Dat T Tran and Dr Ilke Akpinar at the Institute of Health Economics and Dr Philip Jacobs at the University of Alberta explore further.
|
|
|
|
Maturing Approaches for the Production of Viral Vectors
Anticipating Advancements
Antony Hitchcock at Cobra Biologics talks supply and demand following the FDA’s prediction that 40 gene therapy products will be licensed by 2020.
|
|
|
|
The Manufacturing- Regulatory Continuum
Connecting ERP and RIM Data
Eric Gaussens PhD at ProductLife Group divulges the findings from a recent roundtable debate among industry experts focussed on improved data exchange.
|
|
|
|
|
|
 |
|
|
 |
News and Press Releases |
 |
PCI Announces Expansion of High Potent Tableting and Powder Modification Capacity
Philadelphia, USA – March 25, 2019 PCI Pharma Services (PCI), full-service provider of specialist outsourced drug manufacturing, clinical trial services, and commercial packaging to the global biopharmaceutical industry, has announced further investment to expand its flagship manufacturing center in Tredegar, Wales.
More info >> |
|
 |
White Papers |
 |
|
By Your Side for a Healthier World
West Pharmaceutical Services, Inc.
Every day, injectable drugs are administered to improve the lives of millions of patients around the world. And every day, West is working by your side to design and manufacture drug packaging and delivery systems that will bring our customers’ drugs from concept to the patient more efficiently, reliably and safely. West understands our customers’ challenges and helps with solutions every step of the way, with cutting-edge production technologies, an unmatched expertise in global regulatory compliance, and an ever-growing knowledge base of pharmaceutical drug product testing, development, packaging and delivery. Whether focused on one piece of the process or an end-to-end solution, West is by your side for a healthier world.
More info >> |
|
 |
Industry Events |
 |
DIA 2019 Global Annual Meeting
23-27 June 2019, San Diego Convention Center
DIA 2019 is more than just a meeting: it’s where
brilliant minds come together to create solutions. Thousands of global
innovators will convene to engage in discussions on today’s hottest topics in
the life sciences field, propose ways to combat daily challenges, and network
to create lasting connections.
More info >> |
|
|
